Aenova Group
Aenova Group is a suppiler of pharmaceutical and healthcare services.
- Company typePrivate
- Founded2008
- HeadquartersGreensboro, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Aenova Group does
Aenova Group is one of the international service providers in the pharmaceuticals and health care industry. Driven by its high standards of quality, innovative technology and a clear orientation to the future, it has evolved into Europe’s leading operator in the development, manufacture and marketing of pharmaceuticals and dietary supplements. Its range comprises solid dosage forms such as soft and hard capsules, tablets, film-coated tablets, dragées and effervescent tablets.
Aenova Group firmographics
Firmographics- Name
- Aenova Group
- Legal name
- Aenova Holding GmbH
- Website
- http://www.aenova-group.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Aenova Group is a suppiler of pharmaceutical and healthcare services.
- Ownership category
- akta.pro rank
Aenova Group industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Aenova Group is headquartered
LocationHeadquarters
- HQ city
- Greensboro
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aenova Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Aenova generates revenue through contract pharmaceutical manufacturing services, providing development and manufacturing capabilities for finished dosage forms and sterile products for pharmaceutical and healthcare companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Aenova Group product offering
Product offeringCore offering
Aenova Group is a pharmaceutical contract development and manufacturing organization (CDMO) that produces solid, semi-solid, liquid, and sterile dosage forms including tablets, capsules, softgels, and injectable drugs. The company serves pharmaceutical and animal health customers with end-to-end services spanning formulation development, analytical services, technology transfer, and commercial-scale manufacturing. It also operates the Aenovation program to accelerate formulation projects and a dedicated animal health manufacturing line.
Product overview
Aenova Group is a worldwide leading contract manufacturer and development organization for the pharmaceutical and healthcare industry. The company operates a multi-module platform offering three integrated service lines: Pharmaceutical Manufacturing (covering tablets, capsules, softgels, sterile injectables, and effervescent products), Development & Technology (formulation development and analytical services), and Animal Health (veterinary pharmaceutical products). The portfolio includes the Aenovation formulation acceleration program as an add-on service to accelerate client drug development timelines.
Differentiator
Problem solved
Functional benefit
Brands
- Aenovation: Formulation acceleration program launched by Aenova to support drug development services market.
Products and services
- Pharmaceutical Manufacturing Contract manufacturing of solid, semi-solid, liquid, and sterile dosage forms including tablets, capsules, softgels, vials, and prefilled syringes for pharmaceutical customers.
- Development & Technology Formulation development, analytical services, and technology transfer support for pharmaceutical customers moving drug products from development to commercial manufacturing.
- Animal Health Dedicated contract manufacturing of veterinary pharmaceuticals and animal health products, including species-specific formulations.
- Aenovation An accelerated formulation development program that helps pharmaceutical customers reduce time-to-market by combining formulation, analytical, and regulatory expertise in a structured engagement.
Companies that use Aenova Group
Customer profileSegments2 records
Ideal customer profiles2 records
Aenova Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aenova Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GalvitacoreIn July 2023, US-based contract manufacturer Aenova Group partnered with Galvita to advance the development and production of oral dosage forms tailored for dysphagia patients. The partnership focuses on specialized oral nutritional supplements and medication for patients with swallowing difficulties.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Aenova Group competitors and assessment
Company assessmentDirect peers
- Siegfried Holding: Swiss-listed pharmaceutical CDMO offering API and finished dosage form manufacturing across oral solids, sterile and niche categories. Directly comparable in scale, European footprint and small-molecule CDMO positioning.
- Recipharm: Swedish-headquartered pharmaceutical CDMO with strong European manufacturing base across solid, semi-solid, sterile and biologics. Direct competitor in finished dosage forms and sterile fill-finish for European pharma clients.
- Fareva: French privately-held pharmaceutical CDMO with broad European manufacturing footprint spanning oral solids, sterile injectables, and topical formulations. Closely comparable mid-sized private European CDMO competitor.
- CordenPharma: CDMO owned by International Chemical Investors Group, offering API and drug product manufacturing including sterile injectables and oral solids. Direct competitor in small-molecule and peptide CDMO services in Europe.
- Hovione: Portuguese privately-held CDMO specialising in API manufacturing, particle engineering and drug product services. Comparable in integrated CDMO service model with strong European base and private ownership.
Broad incumbents
- Lonza Group: Swiss-listed global leader in CDMO services with dominant scale across biologics, cell & gene therapy and small molecules. Operates in many of the same pharmaceutical CDMO categories as Aenova but at substantially larger scale.
- Catalent: US-headquartered global CDMO (acquired by Novo Holdings in 2024) with broad capabilities including softgel, oral solids, sterile injectables and biologics. Direct competitor in softgel and sterile fill-finish with global reach.
- Thermo Fisher Scientific (Patheon): Operates Patheon pharmaceutical CDMO services offering API, oral solid, sterile and biologics manufacturing globally. Broad incumbent with overlapping small-molecule and sterile CDMO capabilities.
Emerging players
- WuXi STA: Chinese CDMO with rapidly expanding global footprint offering API and drug product services. Emerging player whose scale-up trajectory reflects industry consolidation dynamics relevant to Aenova's positioning.
- Alcami Corporation: US-headquartered CDMO offering sterile injectables, oral solids and API development. Comparable in mid-scale contract manufacturing services, particularly in sterile fill-finish.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Aenova Group social profiles
Digital presenceAenova Group compliance and trust
Trust signalCompliance1 record
Aenova Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aenova Group leadership team
Management profileNumber of profiles
Profiles3 records
Aenova Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aenova Group M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aenova Group
What does Aenova Group do?
Aenova Group is a pharmaceutical contract development and manufacturing organization (CDMO) that produces solid, semi-solid, liquid, and sterile dosage forms including tablets, capsules, softgels, and injectable drugs. The company serves pharmaceutical and animal health customers with end-to-end services spanning formulation development, analytical services, technology transfer, and commercial-scale manufacturing. It also operates the Aenovation program to accelerate formulation projects and a dedicated animal health manufacturing line.
Is Aenova Group a public or private company?
Aenova Group is a private company. It is classified as unknown and is currently operating.
When was Aenova Group founded?
Aenova Group was founded in 2008. It employs 5,001 to 10,000 people.
Where is Aenova Group based?
Aenova Group is headquartered in Greensboro, United States, in the North America region.
How does Aenova Group make money?
One revenue line is on record: contract Manufacturing Services.
Who are Aenova Group's main competitors?
Direct peers on record are Siegfried Holding, Recipharm, Fareva, CordenPharma and Hovione. Broad incumbents are Lonza Group, Catalent and Thermo Fisher Scientific (Patheon). Emerging players are WuXi STA and Alcami Corporation.
Does Aenova Group have an API?
No public API is recorded for Aenova Group.
What industry is Aenova Group in?
Aenova Group's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 32541 and its SIC code is 2834.